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GROWTH FACTOR THERAPY AND
LONG-TERM OUTCOME IN DIABETIC
MACULAR EDEMA
An Independent Analysis of Protocol i Study
Data
PRAVIN U. DUGEL, MD,*† JOANNA H. CAMPBELL, PHD,‡ SZILÁRD KISS, MD,§
ANAT LOEWENSTEIN, MD,¶ VANESSA SHIH, PHARMD,‡ XIAOSHU XU, MS,‡
NANCY M. HOLEKAMP, MD,** ALBERT J. AUGUSTIN, MD, PHD,†† ALLEN C. HO, MD,‡‡
VICTOR H. GONZALEZ, MD,§§ SCOTT M. WHITCUP, MD¶¶
Purpose: This post hoc analysis explores the relationship between early retinal
anatomical response and long-term anatomical and visual outcomes with ranibizumab in
center-involved diabetic macular edema.
Methods: Eyes randomized to the ranibizumab plus prompt laser and ranibizumab plus
deferred laser treatment arms in the Protocol I study were categorized according to their
proportional reduction (,20 vs. $20%) in central retinal thickness (CRT) after 12 weeks.
Adjusted and unadjusted analyses assessed the association between early (Week 12)
anatomical response and long-term (Weeks 52 and 156) anatomical and best-corrected
visual acuity outcomes.
Results: Of 335 study eyes, 118 showed limited (,20%) and 217 showed strong ($20%)
CRT reduction at Week 12. In unadjusted and adjusted analyses, limited early CRT
response was negatively and significantly associated with strong CRT response at Weeks
52 and 156. Sensitivity analyses indicated that this association was robust and unrelated to
any “floor effect.” In unadjusted analyses, a strong early CRT response was associated with
greater long-term improvement in best-corrected visual acuity; after controlling for con-
founders, the association lost statistical significance.
Conclusion: Early CRT response to ranibizumab is a significant prognostic indicator of
medium- to long-term anatomical outcome in center-involved diabetic macular edema.
RETINA 39:88–97, 2019
Diabetic macular edema (DME), a frequent micro-vascular complication of Type 1 and 2 diabetes,1
is characterized by vascular leakage and accumulation
of extracellular fluid in the macula because of break-
down of the blood-retinal barrier.2 Disruption of reti-
nal architecture (e.g., vitreoretinal interface
abnormalities, loss of retinal inner layer boundaries,
cell displacement by cystoid cavities, and neuroretinal
detachment) associated with long-standing retinal
edema3–6 may result in neuronal cell loss and compro-
mised retinal function.7 Macular edema is the main
cause of visual impairment in diabetic patients,8 with
symptomatic vision loss occurring when macular
thickening involves or threatens the fovea.2
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Vascular endothelial growth factor-A (VEGF-A) is
a potent vasopermeability factor closely implicated in
disruption of the blood-retinal barrier in DME,9–11
making it a promising target for pharmacological inter-
vention. Randomized clinical trials of the intravitreal
anti-VEGF-A agents ranibizumab and aflibercept in
eyes with center-involved DME have demonstrated
their efficacy as monotherapy in comparison with laser
photocoagulation in improving visual acuity12–14 and
reducing central retinal thickness (CRT).13 Currently,
intravitreal anti-VEGF-A agents are the treatment of
choice for DME with central involvement.2 Neverthe-
less, even with the intensive treatment schedules used
in clinical trials, the morphologic and visual responses
to anti-VEGF-A therapy are often incomplete, with
20% to 65% of eyes failing to achieve resolution
of retinal thickening12,15–17 and 30% to 70% of eyes
showing ,10-letter improvement in best-corrected
visual acuity (BCVA)12,13,15,18–21 after 1 year or 2
years of treatment.
Persistent and/or recurrent macular edema has been
implicated as a possible contributory factor to poor
visual outcome with ranibizumab therapy in
DME.22,23 Optical coherence tomography (OCT) pro-
vides an accurate and reliable measure of CRT in
DME, enabling quantitative longitudinal monitoring
of macular edema and its response to treatment.24,25
In the era of anti-VEGF-A–directed treatment of
center-involved DME, OCT-derived retinal thickness
has become a widely used quantitative end point in
major clinical studies of DME.26 As a demonstration
of the importance attached to OCT assessment in the
management of DME, the Diabetic Retinopathy Clin-
ical Research Network (DRCR.net) studies of intravi-
treal ranibizumab in the treatment of DME routinely
use OCT-derived CRT response as a measure of treat-
ment efficacy and the need for retreatment.27
Early identification of those patients for whom long-
term anti-VEGF-A therapy is likely to confer that only
limited visual benefit would enable more timely
consideration of additional disease management strate-
gies. To this end, the EARLY (Early Anti-VEGF
Response and Long-term efficacy) program, a series
of post hoc analyses of data from one of the largest
studies of ranibizumab in DME—the Protocol I
study15—was undertaken to explore the relationship
between early and long-term anatomical and visual acu-
ity outcomes of ranibizumab therapy. The primary
objective of the present analysis was to assess whether
retinal anatomical response after 12 weeks of ranibizu-
mab therapy offered any indication of likely anatomical
response at 1 year and 3 years. A secondary objective
was to explore further the possible association between
early anatomical and long-term visual acuity outcomes.
Patients and Methods
Protocol I Study Overview
Protocol I was a prospective, multicenter Phase III
study conducted by the Diabetic Retinopathy Clinical
Research Network (DRCR.net) of intravitreal ranibizu-
mab and triamcinolone in patients with center-involved
DME (clinicaltrials.gov identifier NCT00445003). The
methodology of this study has been detailed else-
where.15 In brief, study eyes (baseline BCVA of 78
to 24 Early Treatment Diabetic Retinopathy Study let-
ters [approximate Snellen equivalent 20/32‒20/320]
and time-domain OCT–determined CRT $250 mm)
were randomly assigned to treatment with 1) intravitreal
ranibizumab 0.5 mg plus prompt (within 7‒10 days)
focal/grid photocoagulation, 2) intravitreal ranibizumab
0.5 mg plus deferred (after $24 weeks) focal/grid
photocoagulation, 3) intravitreal triamcinolone 4 mg
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plus prompt focal/grid photocoagulation, or 4) sham
injection plus prompt focal/grid photocoagulation. In-
travitreal injections were performed at 4-week intervals
for the first 12 weeks (or for the first 20 weeks if DME
persisted) and as needed thereafter; repeat use of laser
was governed by the extent of central macular edema.
Use of alternative DME treatments was allowed only if
prespecified treatment failure or futility criteria were
met. Follow-up examinations, including measurements
of BCVA and OCT (Stratus, Carl Zeiss Meditec Inc,
Dublin, CA)-derived CRT, were performed every 4
weeks for the first year and every 4 weeks to 16 weeks
thereafter. Patient follow-up was planned for 3 years,
with the primary efficacy end point being the mean
change in BCVA at 1 year.15 Review of study findings
at 2 years indicated an efficacy advantage in the ranibi-
zumab treatment arms,28 and patients in the sham injec-
tion and intravitreal triamcinolone treatment arms were
offered the option of switching to open-label ranibizu-
mab for the third year. Follow-up findings for the subset
of eyes randomized to ranibizumab plus prompt or
deferred laser treatment were reported at 3 years29 and
5 years.30
Anatomical and Visual Response Analysis
This analysis is based on 3-year follow-up data for
those Protocol I study eyes that were randomized to
ranibizumab plus prompt or deferred laser treatment and,
in addition, provided an observed CRT measurement at
Week 12. Eligible eyes were categorized according to
their proportional change from baseline in CRT at Week
12: 1) eyes with ,20% reduction (“limited early CRT
response”) and 2) eyes with $20% reduction (“strong
early CRT response”). Serial (4-weekly) CRT and
BCVA readings over Weeks 12 to 156 were collected
for the 2 cohorts; missing readings were imputed using
the last-observation-carried-forward technique. Central
retinal thickness and BCVA readings obtained after ini-
tiation of add-on treatment were also included in the
analysis. Anatomical response over the 3-year follow-
up period was expressed as the proportion of eyes with
$20% reduction in CRT from baseline; visual acuity
response was expressed as the mean absolute change
from baseline in BCVA (Early Treatment Diabetic Ret-
inopathy Study letters). To assess the robustness of any
observed association between early and long-term ana-
tomical response (as expressed by the percent reduction
in CRT), a sensitivity analysis was conducted in eyes
categorized according to the change in logarithmically
transformed OCT-derived CRT (logOCT) value (,1
log-step, 1–2 log-step, and .2 log-step improvement)
at Week 12. For this analysis, anatomical response
over the 3-year follow-up period was expressed as the
proportion of eyes with .2 log-step OCT improvement
from baseline. A 1-step reduction in logOCT equates to
20% reduction in CRT, whereas a 2-step reduction
equates to 36% reduction in CRT, irrespective of base-
line CRT.31 To address the possibility that any demon-
strated association between early and late anatomical
response might be attributable to the limited scope for
CRT reduction in eyes with mild retinal thickening (the
“floor effect”), a sensitivity analysis was performed in
eyes with baseline CRT $350 mm.
Statistical Methods
Intercohort comparisons of baseline characteristics,
as well as anatomical responses (proportion of eyes
with $20% reduction from baseline in CRT) and
visual responses (mean change from baseline in
BCVA) over the study period were performed using
Student’s t-test or Kruskal–Wallis 1-way analysis of
variance for continuous variables and Pearson chi-
square test for categorical variables. Multiple linear
and logistic regression analyses were performed on
long-term (Weeks 52 and 156) anatomical responses
($20% CRT reduction, and .2 log-step OCT
improvement from baseline) and visual acuity out-
come (BCVA change from baseline). In addition to
early anatomical response (either ,20% vs. $20%
CRT reduction or ,1 log-step and 1–2 log-step vs.
.2 log-step OCT improvement at Week 12), covari-
ates included in the regression models were age, sex,
baseline BCVA and CRT, previous receipt of DME
treatment, BCVA change at Week 12, and cumulative
number of ranibizumab injections and laser treatments
received at Week 52 or 156. P values were determined
using Student’s t-test (linear regression) and Wald chi-
square test (logistic regression). Statistical analyses
were performed with SAS versions 9.3 and 9.4 (SAS
Inc, Cary, NC). All tests were 2-tailed and a P value of
#0.05 was considered statistically significant.
Results
The Protocol I study allocated a total of 375 eyes to
treatment with ranibizumab plus either prompt or
deferred laser; of these, 335 eyes provided OCT-
derived CRT data (and corresponding visual acuity data)
at Week 12 and were included in the present analysis.
Association Between Early and Long-Term
Anatomical Response
Within the overall study population (335 eyes), 118
eyes (35.2%) showed ,20% CRT reduction (mean
absolute CRT change from baseline 224 mm) and 217
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eyes (64.8%) showed $20% CRT reduction (mean
absolute CRT change from baseline 2183 mm) at Week
12. Comparison of the 2 cohorts over the 3-year study
period indicated that of the eyes with a limited early CRT
response (n = 118), 37 (31.4%) and 61 (51.7%) subse-
quently achieved a $20% reduction in CRT by Weeks
52 and 156, respectively, whereas of the eyes with
a strong early CRT response (n = 217), 182 (83.9%)
and 180 (82.9%) maintained the initial $20% reduction
in CRT at Weeks 52 and 156, respectively (Figure 1).
Unadjusted analysis indicated that eyes with a limited
early CRT response were significantly (P, 0.0001) less
likely to demonstrate a $20% reduction in CRT at
Weeks 52, 104, and 156 than eyes with a strong early
CRT response (Figure 1).
A limited initial anatomical response to ranibizumab
did not preclude a further decrease in CRT with
continued treatment. Among the cohort of study eyes
with limited early CRT response (n = 118), 37 (31.4%)
eyes subsequently achieved a $20% reduction in CRT
by Week 52 (“slow responders”), whereas the remaining
81 (68.6%) eyes continued to show ,20% reduction in
CRT at Week 52 (“non-responders”). Subsequent
response rates (proportion of eyes with $20% reduction
in CRT) remained high in slow-responder eyes (91.9 and
86.5% at Weeks 104 and 156, respectively) but, despite
a gradual improvement over time, were significantly
(P , 0.001) lower in nonresponder eyes (23.5 and
35.8% at Weeks 104 and 156, respectively).
The significant association between early and long-
term anatomical response to ranibizumab demon-
strated in the unadjusted analysis persisted after
controlling for potential confounding variables. Sig-
nificant differences in demographic and baseline
clinical characteristics and treatment intensity were
noted between cohorts categorized by their
proportional CRT response at Week 12 (Table 1).
For example, eyes with$20% CRT reduction at Week
12 were younger (mean 61.5 vs. 65.0 years of age; P =
0.002), had lower baseline BCVA (mean 61.6 vs. 65.4
Early Treatment Diabetic Retinopathy Study letters;
P = 0.004), and higher baseline CRT (433 vs.
345 mm; P , 0.001) and, as expected from their
strong initial anatomical response, received fewer ra-
nibizumab injections (mean 12.7 vs. 15.1; P = 0.005)
and laser procedures (mean 1.7 vs. 2.4; P = 0.005)
over the 3-year follow-up period than eyes with
,20% CRT reduction at Week 12. Multiple logistic
regression analysis with adjustment for differences in
baseline parameters (age, sex, previous DME treat-
ment, and baseline BCVA and CRT) indicated that
,20% CRT reduction at Week 12 showed a significant
negative association with $20% CRT reduction at
Week 52 (odds ratio [OR] 0.11, 95% confidence inter-
val [CI] 0.06–0.19; P , 0.001) and Week 156 (OR
0.35, 95% CI 0.20–0.61; P , 0.001). Of the other
covariates included in this regression model, baseline
BCVA and baseline CRT were significantly (posi-
tively) associated with $20% CRT reduction at Week
52, whereas baseline CRT remained significantly asso-
ciated with $20% CRT reduction at Week 156. An
expanded regression model that additionally adjusted
for differences in treatment intensity over the 3-year
study period likewise indicated that ,20% CRT
reduction at Week 12 was significantly (negatively)
associated with $20% CRT reduction at Week 52
(OR 0.13, 95% CI 0.07–0.24; P , 0.001) and Week
156 (OR 0.45, 95% CI 0.25–0.81; P = 0.008)
(Table 2). In this model, baseline CRT and cumulative
number of ranibizumab injections were also signifi-
cantly associated with $20% CRT reduction at Weeks
52 and 156 (Table 2).
Fig. 1. Proportional CRT
response over the 3-year follow-
up period, categorized by pro-
portional CRT response at Week
12. *P , 0.0001 at Weeks 52,
104, and 156, intercohort
comparison.
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Sensitivity Analyses
Sensitivity analyses indicated that the association
between early and long-term anatomical response to
ranibizumab was robust and was unlikely to be due to
a possible “floor effect.” Early-response cohorts obtained
by stratification of the study eye population according to
logOCT improvement at Week 12 (,1 log-step [116
eyes, 34.6%]; 1–2 log-step [110 eyes, 32.8%]; and .2
log-step [109 eyes, 32.5%]) showed significant overall
differences in age, sex, baseline BCVA and CRT, pro-
portion of eyes with baseline CRT ,400 mm, change
from baseline in BCVA at Week 12, and cumulative
number of ranibizumab injections and laser procedures
received at Weeks 52 and 156. Multiple logistic regres-
sion with adjustment for the covariates included in the
expanded regression model of the main analysis indi-
cated that ,1 log-step OCT improvement at Week 12
showed a significant negative association with .2 log-
step OCT improvement at Week 52 (OR 0.06, 95% CI
0.02–0.15; P , 0.001) and at Week 156 (OR 0.36, 95%
CI 0.17–0.77; P = 0.009). A statistically significant
negative association was also demonstrated between
1-2 log-step OCT improvement at Week 12 and .2
log-step OCT improvement at Week 52 (OR 0.27,
95% CI 0.14–0.53; P , 0.001) and at Week 156 (OR
0.39, 95% CI 0.20–0.79; P = 0.009).
Table 1. Baseline Demographics, Clinical Characteristics, and Treatment Intensity of Pooled Study Eyes, Categorized by
Proportional CRT Response at Week 12 (N = 335)
Baseline Characteristics
Proportional CRT Response at Week 12
P*,20% CRT Reduction n = 118 $20% CRT Reduction n = 217
Age, mean ± SD, years 65.0 ± 9.1 61.5 ± 9.8 0.002
Male sex, n (%) 76 (64.4) 112 (51.6) 0.024
Previous DME treatment, n (%) 82 (69.5) 123 (56.7) 0.022
Baseline BCVA, mean ± SD (letters) 65.4 ± 10.9 61.6 ± 11.8 0.004
Baseline CRT, mean ± SD, mm 345 ± 83 433 ± 131 ,0.001
Baseline CRT ,400 mm, n (%) 89 (75.4) 101 (46.5) ,0.001
BCVA CFB at Week 12, mean ± SD
(letters)
3.6 ± 6.8 9.2 ± 7.7 ,0.001
CRT CFB at Week 12, mean ± SD, mm 224.1 ± 33.5 2182.6 ± 115.7 ,0.001
Cumulative no. of RAN injections at
Week 52, mean ± SD
9.8 ± 3.0 7.9 ± 2.9 ,0.001
Cumulative no. of RAN injections at
Week 156, mean ± SD
15.1 ± 7.9 12.7 ± 7.2 0.005
Cumulative no. of laser procedures at
Week 52, mean ± SD
1.6 ± 1.3 1.1 ± 1.2 ,0.001
Cumulative no. of laser procedures at
Week 156, mean ± SD
2.4 ± 2.1 1.7 ± 1.9 0.005
CFB, change from baseline; RAN, ranibizumab.
*Intercohort comparison, based on Student’s t-test for continuous variables, and Pearson chi-square test for categorical variables.
Table 2. Multiple Logistic Regression Analysis on $20% Reduction in CRT at Weeks 52 and 156: Pooled Study
Eyes (N = 335)
Parameter
Multiple Logistic Regression on $20% Reduction in CRT at Weeks 52 and 156
Week 52, N = 335 Week 156, N = 335
OR (95% CI) P* OR (95% CI) P*
Age 1.01 (0.98–1.04) 0.550 0.99 (0.97–1.02) 0.738
Sex (female/male) 0.95 (0.54–1.68) 0.852 1.02 (0.58–1.79) 0.950
Baseline BCVA 1.03 (1.00–1.06) 0.063 1.02 (0.99–1.05) 0.161
Baseline CRT† 2.70 (1.00–2.70) ,0.001 2.70 (2.70–2.70) ,0.001
Previous DME treatment (yes/no) 1.00 (0.56–1.81) 0.987 1.11 (0.61–2.01) 0.728
,20% CRT reduction at Week 12 0.13 (0.07–0.24) ,0.001 0.45 (0.25–0.81) 0.008
Cumulative no. of RAN injections 0.89 (0.79–0.99) 0.030 0.92 (0.87–0.96) ,0.001
Cumulative no. of laser procedures 1.11 (0.88–1.40) 0.397 1.04 (0.89–1.22) 0.598
RAN, ranibizumab.
*P value based on Wald chi-square test for OR = 1.
†Baseline CRT as expressed in 100 mm units.
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Among the subset of eyes with baseline CRT $350
mm (n = 199), 46 eyes (23.1%) and 153 eyes (76.9%)
showed,20% and$20% CRT reduction, respectively,
at Week 12. Multiple logistic regression analysis, ad-
justing for baseline parameters (age, baseline BCVA,
baseline CRT, and previous DME treatment), and on-
study treatment intensity (cumulative number of ranibi-
zumab injections and laser procedures), indicated that
$20% CRT reduction at Week 12 was significantly
associated with $20% CRT reduction at Week 52
(OR 7.23, 95% CI 2.88–18.18; P , 0.001) but not at
Week 156 (OR 1.24, 95% CI 0.48–3.20; P = 0.658).
Association Between Early Anatomical Response
and Long-Term Visual Response
A strong early CRT response to ranibizumab was
associated with greater long-term improvement in
visual acuity; however, after controlling for potential
confounders, the association was attenuated and
statistical significance was lost (Table 3). Unadjusted
analyses indicated that the mean improvement from
baseline in BCVA at all time points over the 3-year
study period was significantly smaller in eyes with
,20% compared with $20% CRT reduction at Week
12 (mean standard deviation [SD] 4.8 [13.5] vs. 11.5
[9.5] letters at Week 52; 4.0 [15.8] vs. 10.4 [12.5]
letters at Week 156; both P, 0.001). After adjustment
for potential confounders (age, sex, baseline BCVA
and CRT, previous DME treatment, BCVA change
from baseline at Week 12, and cumulative number
of ranibizumab injections and laser procedures
received over the study period) using multiple linear
regression, $20% CRT reduction at Week 12 was no
longer significantly associated with BCVA response
(change from baseline) at Week 52 (estimate [standard
error, SE] 1.59 [1.25]; P = 0.205) or Week 156 (esti-
mate [SE] 1.88 [1.70]; P = 0.268) (Table 3).
Discussion
This post hoc analysis of data from the DRCR.net
Protocol I study indicates that retinal morphologic
responses to ranibizumab plus prompt or deferred laser
treatment generally develop rapidly in patients with
center-involved DME, with two-thirds of eyes achiev-
ing a $20% reduction in CRT within the first 3
months of treatment. For eyes in this early-response
category, the initial anatomical improvement was
largely maintained during long-term treatment, with
83% of eyes continuing to show$20% CRT reduction
at 3 years. By contrast, for the one-third of eyes that
showed little or no anatomical improvement after the
first 3 ranibizumab injections, prospects for future
improvement with continued treatment were at best
moderate, with 48% of eyes continuing to show
,20% CRT reduction at 3 years, despite the intensive
treatment and monitoring protocol. This would imply
that resolution of macular edema after an initially lim-
ited treatment response is less readily achievable than
maintenance of remission after a strong early treatment
response. In those eyes that did subsequently develop
a fuller anatomical response with continued treatment,
improvement was generally slow: among the eyes with
limited early CRT response, 31% showed $20% CRT
reduction at 1 year, rising to 45% at 2 years, and 52%
at 3 years. Unadjusted and adjusted analyses indicated
that, at the cohort level, proportional CRT response
(,20 vs. $20% reduction) at Week 12 was signifi-
cantly associated with proportional CRT response over
3 years of follow-up. Using another parameter of rel-
ative anatomical change—the log-transformed
Table 3. Multiple Linear Regression Analysis on BCVA Change From Baseline at Weeks 52 and 156: Pooled Study Eyes
(N = 335)
Parameter
Multiple Linear Regression on BCVA Change from Baseline at Weeks 52 and 156
Week 52, N = 335 Week 156, N = 335
Estimate (SE) P* Estimate (SE) P*
Age 20.13 (0.05) 0.016 20.10 (0.07) 0.162
Sex (female/male) 0.01 (1.01) 0.991 0.66 (1.43) 0.644
Baseline BCVA 20.22 (0.05) ,0.001 20.25 (0.07) ,0.001
Baseline CRT 20.01 (0.00) 0.061 20.00 (0.01) 0.946
Previous DME treatment (yes/no) 22.02 (1.04) 0.054 20.16 (1.47) 0.914
BCVA CFB at Week 12 0.72 (0.07) ,0.001 0.56 (0.10) ,0.001
$20% CRT reduction at Week 12 1.59 (1.25) 0.205 1.88 (1.70) 0.268
Cumulative no. RAN injections 20.09 (0.19) 0.658 0.04 (0.11) 0.721
Cumulative no. laser procedures 20.66 (0.42) 0.116 20.16 (0.39) 0.684
CFB, change from baseline; RAN, ranibizumab.
*P value based on Student’s t-test.
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reduction in excess retinal thickness, based on a “nor-
mal” CRT of 200 mm32 (i.e., the change in logOCT)—
we likewise demonstrated a significant association
between CRT response at Week 12 and CRT response
at 1 year and 3 years, which attests to the robustness of
this relationship.
Our finding that a strong anatomical response ($20%
CRT reduction)—whether obtained at Week 12, 52, or
156—was associated with a higher baseline CRT is
consistent with reports that the greatest reductions in
CRT produced by ranibizumab in DME occur in eyes
with highest baseline CRT.15,18,33 Because baseline
CRT is a significant determinant of subsequent CRT
response to ranibizumab therapy, it is feasible that the
observed association between early and late anatomical
response might be driven in part by a “floor effect” on
the amount of CRT reduction that is possible in eyes
with mild retinal thickening. For example, an eye with
a baseline CRT of 250 mm (the threshold value required
for Protocol I study eligibility) would be limited to
a maximum possible CRT reduction of 50 mm (20%
improvement), assuming a “normal” OCT-derived CRT
value of 200 mm.32,34,35 The demonstration of a signif-
icant association between early and late anatomical
response in the subset of eyes with baseline CRT
$350 mm (i.e., eyes with the potential for substantial
reductions in retinal thickness) would, however, argue
against a “floor effect.” Moreover, findings from a pre-
vious analysis of Protocol I study data, which assessed
a total of 37 baseline variables for association with
1-year anatomical and visual acuity outcomes in the
ranibizumab plus prompt and deferred laser treatment
arms, would suggest that the observed relationship
between early and late anatomical outcome in
ranibizumab-treated eyes is real.33 To negate the possi-
ble influence of a “floor effect,” the analysis chose as its
parameter of anatomical response the percent reduction
in excess retinal thickness, as defined by a CRT thresh-
old of 250 mm (i.e., a value above the “normal” CRT of
200 mm). The demonstration that higher baseline CRT
was associated with a greater percent reduction in
excess retinal thickness, suggests that the relationship
is unrelated to any “floor effect.”33
Eyes with strong compared with limited early
anatomical response to ranibizumab showed signifi-
cantly greater improvement in visual acuity over the
follow-up period, although intersubject variability in
BCVA response was pronounced in both groups.
However, eyes showing a strong early anatomical
response also had significantly lower baseline BCVA
and higher baseline CRT values, which are factors
favoring visual acuity improvement with ranibizu-
mab.15,18,33 After adjusting for these and other poten-
tial confounders, the multiple regression model
revealed no significant association between OCT-
derived early anatomical response ($20% CRT reduc-
tion at Week 12) and BCVA improvement at either 1
year or 3 years. Previous investigations of the relation-
ship between the anatomical and functional outcomes
of anti-VEGF-A therapy in DME have yielded incon-
sistent results.22,23,33,36 An independent post hoc anal-
ysis of the Protocol I study data (ranibizumab plus
prompt and deferred laser treatment arms) has sug-
gested that early and sustained CRT reduction during
ranibizumab treatment is associated with a better long-
term visual acuity outcome.33 Eyes showing an early
and consistent anatomical response during the first
year of ranibizumab treatment ($20% CRT reduction
at Weeks 16, 32, and 52) showed greater BCVA
improvement at Week 52 (mean 13 letters) than eyes
with an early but inconsistent response ($20% CRT
reduction at Week 16 but not at Week 32 and/or 52)
(mean 9 letters), eyes with a slow and variable
response ($20% CRT reduction at Week 32 and/or
52) (mean 7 letters) and nonresponders (mean 4 let-
ters).33 A subsequent post hoc analysis of the Protocol
I study data, conducted in the subset of ranibizumab
plus prompt/deferred laser-treated study eyes that
showed persistent macular thickening through the first
24 weeks of ranibizumab treatment (n = 117), found
that long-term (3-year) visual acuity outcome was sig-
nificantly worse in eyes with chronic persistent edema
through the entire 3-year follow-up period than in eyes
with shorter lasting edema (mean BCVA improvement
from baseline to 3 years: 7 vs. 13 letters).23 (Eyes were
considered to have chronic persistent edema until they
achieved a CRT ,250 mm and $10% reduction rela-
tive to Week 24 at 2 consecutive study visits subse-
quent to Week 24.) Nevertheless, eyes with persistent
macular edema through 3 years still achieved substan-
tial reductions in CRT over this period (median CRT
declined from 396 mm [baseline] to 278 mm [3 years]),
consistent with the improvement in visual acuity.23 By
contrast, analysis of RISE/RIDE and READ-2 study
data suggests a dissociation between early anatomical
and long-term visual acuity responses to ranibizumab
in DME.22,36 An earlier DRCR.net study reported
modest correlation between OCT-derived CRT and
visual acuity in DME, and modest correlation between
the change in CRT and change in visual acuity after
focal laser photocoagulation.37 However, the range of
BCVA values observed for any given degree of retinal
edema was large, and CRT was found to account for,
at most, only one-quarter of the variability in visual
acuity.37 Detailed information on the spatial distribu-
tion of retinal thickness and the integrity of individual
retinal layers may be required to establish a more
consistent structural–functional relationship in
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DME.3,5,38,39 In addition, given the progressive course
of retinal vascular leakage40 and retinal structural
damage41,42 in DME, longitudinal assessment of CRT
over time may provide a better measure of the effect of
persistent macular edema on visual acuity.
Strengths of this analysis include its large sample
size, randomized study design and standardized re-
treatment protocol, extended follow-up duration, and
use of OCT methodology. Although the Protocol I
study used time-domain OCT scanning, which pro-
vides poorer axial resolution and retinal layer delin-
eation than the spectral domain OCT devices currently
available in clinical practice,25 time-domain OCT
measurements are nevertheless reproducible and cor-
relate with other morphometric parameters of macular
anatomy in DME,43 as well as with fluorescein angio-
graphic findings.44,45 Accordingly, time-domain OCT
has been used extensively for quantification of DME
severity and as a surrogate marker of treatment
response.43,46,47 Limitations of the analysis include
its post hoc design, potential bias arising from use of
the last-observation-carried-forward technique for
imputation of missing CRT and BCVA values, and
the absence of information on additional factors such
as DME clinical subtype (focal vs. diffuse) and mor-
phologic pattern (diffuse retinal thickening, cystoid
macular edema, serous retinal detachment, and vitre-
omacular interface abnormalities) that are known to
influence anatomical and visual acuity responses to
anti-VEGF-A therapy.33,48–51
In conclusion, for physicians who primarily use
OCT as a treatment guide, this analysis indicates that
early (Week 12) CRT response to ranibizumab is
a significant prognostic indicator of medium- to long-
term anatomical outcome in DME. Although a limited
early CRT response to ranibizumab does not preclude
further anatomical improvement with continued treat-
ment, consolidation of the anatomical response in
these circumstances is generally protracted, and falls
short of the therapeutic objective of achieving timely
elimination of subretinal and intraretinal fluid.
Key words: anti-VEGF, central retinal thickness,
diabetic macular edema, optical coherence tomogra-
phy, ranibizumab, retinal morphology, retrospective
analysis, visual acuity.
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